IL1B and COVID-19: As the prevalence of neurological complications due to COVID-19 is relatively higher in more severe patients and an increase in cytokines correlates to a worse clinical prognosis, the use of citicoline may also be advantageous as it decreases the cytokines MIP-1α, TNFα, IL-1β, MCP-1 secretions, IL-6, RANTES, and the anti-inflammatory cytokine IL-10 secretions [182,188].